Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy

Eye

Volumn 24, Issue 8, 2010, Pages 1315-1319

  Hornan, D ^a   Edmeades, N ^a   Krishnan, R ^a   Khan, J ^a   Lochhead, J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

diabetic retinopathy; pegaptanib; vitreous haemorrhage

Indexed keywords

PEGAPTANIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; PREOPERATIVE CARE; RECURRENT DISEASE; RETINA DETACHMENT; RISK FACTOR; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 77955612774     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.14     Document Type: Article

References (24)

1. Ziemianski MC, McMeel JW, Franks EP. Natural history of vitreous hemorrhage in diabetic retinopathy. Ophthalmology 1980; 87(4): 306-312.
2. Yang CM. Surgical treatment for diabetic retinopathy: 5-Year experience. J Formos Med Assoc 1998; 97(7): 477-484.
3. Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina 2005; 25(7): 815-827.
4. Adamis AP, Altaweel M, Bressler NM, Cunningham ET, Davis MD, Goldbaum M et al. Changes in retinal neovascularization after pegaptanib (macugen) therapy in diabetic individuals. Ophthalmology 2006; 113(1): 23-28.
5. Krzystolik MG, Filippopoulos T, Ducharme JF, Loewenstein JI. Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. Arch Ophthalmol 2006; 124(6): 920-921.
6. Bansal AG, Narayanan R, Majji AB, Thomas R. Neovascular changes after pegaptanib in diabetics. Ophthalmology 2007; 114(3): 615-616.
7. Mendrinos E, Donati G, Pournaras CJ. Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmol 2009; 87(6): 683-684.
8. Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, DAmico DJ et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112(10): 1747-1757.
9. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E et al. Pegaptanib sodium for neovascular age-related macular degeneration: Third-Year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92(12): 1606-1611.
10. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N et al. Vascular endothelial growth factor-a is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171(1): 53-67.
11. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009; 40(1): 68-70.
12. Neubauer AS, Kook D, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW et al. Bevacizumab and retinal ischemia. Ophthalmology 2007; 114(11): 2096.
13. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008; 86(8): 925-927.
14. Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008; 28(7): 957-963.
15. Mitry D, Schmoll C, Hegde V, Borooah S, Singh J, Bennett H. Use of pegaptanib in the treatment of vitreous haemorrhage in idiopathic retinal vasculitis. Eye 2008; 22(11): 1449-1450.
16. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clearup after diabetic vitrectomy. Am J Ophthalmol 2008; 146(2): 211-217.
17. Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008; 36(5): 449-454.
18. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009; 23(1): 108-111.
19. Spaide RF, Fisher YL. Intravitreal bevacizumab (avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26(3): 275-278.
20. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008; 86(6): 683-687.
21. Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF et al. Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009; 23(1): 117-123.
22. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246(12): 1699-1705.
23. Krishnan R, Goverdhan S, Lochhead J. Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye 2009; 23(5): 1238-1239.
24. Tranos P, Gemenetzi M, Papandroudis A, Chrisafis C, Papadakos D. Progression of diabetic tractional retinal detachment following single injection of intravitreal avastin. Eye 2008; 22(6): 862.